Payment overview · 2025
General Payments
$2,162.27
40 reported records · 19 companies
Healthcare provider profile · identity verified
Peter C Chi, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · TEMPLE CITY, CA · NPI 1023090867
Verified facts
What the public records show
CMS Open Payments records show Peter C Chi, M.D. received $2,162.27 in general payments during 2025 across 40 reported records.
Teva Pharmaceuticals USA, Inc. accounted for 11.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 24 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Jardiance, Kerendia, Mounjaro, Ozempic, Rexulti, Ubrelvy.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported UBRELVY as an associated drug or biological on 299803 records involving 61203 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Ubrelvy by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Prolia by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 135 claims for Farxiga by this doctor in 2024.
Bayer Healthcare Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Kerendia as an associated drug or biological on 138674 records involving 48458 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Kerendia by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 327 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Shingrix by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 327 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 76 claims for Mounjaro by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 84 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 60 claims for Rybelsus by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NUEDEXTA as an associated drug or biological on 393 records involving 285 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Nuedexta by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Rexulti by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $245.92 | 11.4% | 2 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $227.57 | 10.5% | 5 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $187.39 | 8.7% | 11 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $167.15 | 7.7% | 2 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $163.37 | 7.6% | 2 | 2025 |
| Madrigal Pharmaceuticals | Unresolved — no canonical attribution shown | $150.00 | 6.9% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $140.00 | 6.5% | 1 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $125.00 | 5.8% | 1 | 2025 |
| Aimmune Therapeutics, Inc. | Unresolved — no canonical attribution shown | $124.99 | 5.8% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $124.99 | 5.8% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $124.03 | 5.7% | 1 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $121.83 | 5.6% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $68.69 | 3.2% | 3 | 2025 |
| PROTEGA PHARMACEUTIALS INC | Unresolved — no canonical attribution shown | $55.77 | 2.6% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $38.68 | 1.8% | 2 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $28.32 | 1.3% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $27.27 | 1.3% | 1 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $23.57 | 1.1% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $17.73 | 0.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $2,162.27 | 40 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $245.92 | 2 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $167.15 | 2 | 2025 |
Source payment records
|
|||||
| Intracept Normalized: intracept |
Device | Boston Scientific Corporation | $163.37 | 2 | 2025 |
Source payment records
|
|||||
| REZDIFFRA Normalized: rezdiffra |
Drug | Madrigal Pharmaceuticals | $150.00 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $140.00 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $133.66 | 9 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $125.00 | 1 | 2025 |
Source payment records
|
|||||
| Leqembi Normalized: leqembi |
Drug | Eisai Inc. | $125.00 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $124.99 | 1 | 2025 |
Source payment records
|
|||||
| ZENPEP Normalized: zenpep |
Drug | Aimmune Therapeutics, Inc. | $124.99 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $124.03 | 1 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $121.83 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $102.57 | 4 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $68.69 | 3 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $68.69 | 3 | 2025 |
Source payment records
|
|||||
| ROXYBOND Normalized: roxybond |
Drug | PROTEGA PHARMACEUTIALS INC | $55.77 | 2 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $53.73 | 2 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $53.73 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $38.68 | 2 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $28.32 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $27.27 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $27.27 | 1 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $23.57 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $17.73 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 135 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 327 | exact normalized | Medicare Part D |
| Kerendia kerendia |
2025 | Kerendia | 2024 | 26 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 76 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 84 | exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 26 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| UBRELVY ubrelvy |
2025 | Ubrelvy | 2024 | 14 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | UBRELVY open payments reported associated product |
CMS Open Payments — General Payments 299803 supporting records · 61203 recipient NPIs · example record 1201352530 |
Ubrelvy · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
20 | 13 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
135 | 32 |
| Bayer Healthcare Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | Kerendia open payments reported associated product |
CMS Open Payments — General Payments 138674 supporting records · 48458 recipient NPIs · example record 1225434663 |
Kerendia · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
327 | 64 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
24 | 16 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
327 | 64 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
76 | 12 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
84 | 18 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
60 | 18 |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | NUEDEXTA open payments reported associated product |
CMS Open Payments — General Payments 393 supporting records · 285 recipient NPIs · example record 1227268901 |
Nuedexta · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1156 | 307 |
| Losartan Potassium | Losartan Potassium | 725 | 170 |
| Amlodipine Besylate | Amlodipine Besylate | 644 | 167 |
| Metformin Hcl | Metformin Hcl | 470 | 129 |
| Jardiance | Empagliflozin | 327 | 64 |
| Eliquis | Apixaban | 311 | 44 |
| Levothyroxine Sodium | Levothyroxine Sodium | 307 | 74 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 301 | 101 |
| Tamsulosin Hcl | Tamsulosin Hcl | 285 | 87 |
| Gabapentin | Gabapentin | 257 | 67 |
| Metoprolol Succinate | Metoprolol Succinate | 244 | 65 |
| Pantoprazole Sodium | Pantoprazole Sodium | 237 | 81 |
| Alendronate Sodium | Alendronate Sodium | 227 | 70 |
| Simvastatin | Simvastatin | 225 | 50 |
| Omeprazole | Omeprazole | 219 | 51 |
| Lisinopril | Lisinopril | 212 | 53 |
| Donepezil Hcl | Donepezil Hcl | 205 | 41 |
| Metoprolol Tartrate | Metoprolol Tartrate | 197 | 38 |
| Famotidine | Famotidine | 194 | 55 |
| Azithromycin | Azithromycin | 182 | 134 |
| Lorazepam | Lorazepam | 181 | 53 |
| Escitalopram Oxalate | Escitalopram Oxalate | 175 | 50 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 172 | 22 |
| Memantine Hcl | Memantine Hcl | 170 | 23 |
| Zolpidem Tartrate | Zolpidem Tartrate | 168 | 38 |
| Clopidogrel | Clopidogrel Bisulfate | 159 | 35 |
| Carvedilol | Carvedilol | 157 | 35 |
| Montelukast Sodium | Montelukast Sodium | 156 | 57 |
| Furosemide | Furosemide | 140 | 43 |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 138 | 52 |
| Pioglitazone Hcl | Pioglitazone Hcl | 138 | 36 |
| Farxiga | Dapagliflozin Propanediol | 135 | 32 |
| Xarelto | Rivaroxaban | 131 | 19 |
| Valsartan | Valsartan | 128 | 33 |
| Mirtazapine | Mirtazapine | 125 | 29 |
| Finasteride | Finasteride | 124 | 37 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 108 | 37 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 102 | 69 |
| Alprazolam | Alprazolam | 101 | 26 |
| Latanoprost | Latanoprost | 93 | 14 |
| Tramadol Hcl | Tramadol Hcl | 93 | 37 |
| Glimepiride | Glimepiride | 91 | 18 |
| Januvia | Sitagliptin Phosphate | 87 | 14 |
| Diclofenac Sodium | Diclofenac Sodium | 86 | 35 |
| Lidocaine | Lidocaine | 84 | 20 |
| Ozempic | Semaglutide | 84 | 18 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 82 | 25 |
| Baclofen | Baclofen | 81 | 21 |
| Quetiapine Fumarate | Quetiapine Fumarate | 81 | 18 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 80 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 80 | 31 |
| Allopurinol | Allopurinol | 79 | 24 |
| Fluticasone Propionate | Fluticasone Propionate | 78 | 34 |
| Temazepam | Temazepam | 78 | 24 |
| Glipizide | Glipizide | 77 | 24 |
| Ibuprofen | Ibuprofen | 77 | 31 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 77 | 12 |
| Potassium Chloride | Potassium Chloride | 77 | 15 |
| Mounjaro | Tirzepatide | 76 | 12 |
| Pravastatin Sodium | Pravastatin Sodium | 76 | 22 |
| Midodrine Hcl | Midodrine Hcl | 75 | 14 |
| Celecoxib | Celecoxib | 73 | 37 |
| Metformin Hcl Er | Metformin Hcl | 70 | 21 |
| Prednisone | Prednisone | 68 | 26 |
| Spironolactone | Spironolactone | 68 | 16 |
| Icosapent Ethyl | Icosapent Ethyl | 65 | 18 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 63 | 19 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 63 | 18 |
| Rybelsus | Semaglutide | 60 | 18 |
| Hydralazine Hcl | Hydralazine Hcl | 59 | 16 |
| Meloxicam | Meloxicam | 59 | 17 |
| Ezetimibe | Ezetimibe | 55 | 14 |
| Fenofibrate | Fenofibrate | 55 | 15 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 54 | 39 |
| Megestrol Acetate | Megestrol Acetate | 51 | 15 |
| Clonazepam | Clonazepam | 50 | 12 |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 50 | 20 |
| Vascepa | Icosapent Ethyl | 49 | 17 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 48 | 14 |
| Nifedipine Er | Nifedipine | 48 | 13 |
| Clonidine Hcl | Clonidine Hcl | 46 | 13 |
| Meclizine Hcl | Meclizine Hcl | 45 | 22 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 44 | 35 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 44 | 15 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 43 | 13 |
| Dexamethasone | Dexamethasone | 42 | 34 |
| Irbesartan | Irbesartan | 42 | 13 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 42 | 12 |
| Humulin R | Insulin Regular, Human | 41 | 11 |
| Levofloxacin | Levofloxacin | 41 | 33 |
| Levetiracetam | Levetiracetam | 40 | 11 |
| Sertraline Hcl | Sertraline Hcl | 39 | 13 |
| Paroxetine Hcl | Paroxetine Hcl | 37 | suppressed |
| Humulin N Kwikpen | Insulin Nph Human Isophane | 35 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 35 | 11 |
| Lactulose | Lactulose | 35 | 13 |
| Paxlovid | Nirmatrelvir/Ritonavir | 35 | 35 |
| Ketoconazole | Ketoconazole | 34 | 20 |
| Olanzapine | Olanzapine | 34 | suppressed |
| Sodium Chloride | 0.9 % Sodium Chloride | 34 | 21 |
| Amoxicillin | Amoxicillin | 33 | 25 |
| Gemfibrozil | Gemfibrozil | 33 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 32 | 26 |
| Azelastine Hcl | Azelastine Hcl | 32 | 12 |
| Breo Ellipta | Fluticasone/Vilanterol | 32 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 32 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 32 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 32 | 11 |
| Nystatin | Nystatin | 31 | 17 |
| Novolog Flexpen | Insulin Aspart | 30 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 30 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 30 | 24 |
| Ondansetron Hcl | Ondansetron Hcl | 29 | 21 |
| Atenolol | Atenolol | 28 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 28 | suppressed |
| Levemir Flexpen | Insulin Detemir | 28 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 27 | suppressed |
| Nuedexta | Dextromethorphan Hbr/Quinidine | 27 | suppressed |
| Praluent Pen | Alirocumab | 27 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 27 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 27 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 26 | 19 |
| Kerendia | Finerenone | 26 | suppressed |
| Myrbetriq | Mirabegron | 26 | suppressed |
| Nabumetone | Nabumetone | 26 | suppressed |
| Pregabalin | Pregabalin | 26 | suppressed |
| Rexulti | Brexpiprazole | 26 | suppressed |
| Sevelamer Carbonate | Sevelamer Carbonate | 26 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 26 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 26 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 26 | suppressed |
| Dextrose In Water | Dextrose 5 % In Water | 25 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 25 | suppressed |
| Colchicine | Colchicine | 24 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 24 | suppressed |
| Fentanyl | Fentanyl | 24 | suppressed |
| Novolog | Insulin Aspart | 24 | suppressed |
| Repatha Sureclick | Evolocumab | 24 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 24 | 16 |
| Dorzolamide Hcl | Dorzolamide Hcl | 22 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 22 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 22 | suppressed |
| Ceftriaxone | Ceftriaxone Sodium | 21 | 13 |
| Cephalexin | Cephalexin | 21 | 21 |
| Clobetasol Propionate | Clobetasol Propionate | 21 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 21 | 15 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 21 | suppressed |
| Dutasteride | Dutasteride | 20 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 20 | suppressed |
| Prolia | Denosumab | 20 | 13 |
| Amiodarone Hcl | Amiodarone Hcl | 19 | suppressed |
| Brimonidine Tartrate | Brimonidine Tartrate | 19 | suppressed |
| Cyclosporine | Cyclosporine | 19 | suppressed |
| Aripiprazole | Aripiprazole | 18 | suppressed |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 18 | suppressed |
| Bethanechol Chloride | Bethanechol Chloride | 18 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 18 | suppressed |
| Entecavir | Entecavir | 18 | suppressed |
| Glipizide-Metformin | Glipizide/Metformin Hcl | 18 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 18 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 18 | suppressed |
| Acarbose | Acarbose | 17 | suppressed |
| Amlodipine-Atorvastatin | Amlodipine/Atorvastatin | 17 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 17 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 17 | suppressed |
| Dorzolamide-Timolol | Dorzolamide Hcl/Timolol Maleat | 16 | suppressed |
| Fluocinonide | Fluocinonide | 16 | suppressed |
| Humulin 70/30 Kwikpen | Insulin Nph Hum/Reg Insulin Hm | 16 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 16 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 16 | suppressed |
| Lyrica | Pregabalin | 16 | suppressed |
| Novolin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 16 | suppressed |
| Ondansetron Odt | Ondansetron | 16 | 11 |
| Ezetimibe-Simvastatin | Ezetimibe/Simvastatin | 15 | suppressed |
| Invokana | Canagliflozin | 15 | suppressed |
| Levemir | Insulin Detemir | 15 | suppressed |
| Linzess | Linaclotide | 15 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 15 | suppressed |
| Lovastatin | Lovastatin | 15 | suppressed |
| Methimazole | Methimazole | 15 | suppressed |
| Santyl | Collagenase Clostridium Hist. | 15 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 15 | suppressed |
| Tradjenta | Linagliptin | 15 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 15 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 14 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 14 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 14 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 14 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 14 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 14 | suppressed |
| Glycopyrrolate | Glycopyrrolate | 14 | suppressed |
| Humalog | Insulin Lispro | 14 | suppressed |
| Methocarbamol | Methocarbamol | 14 | suppressed |
| Ubrelvy | Ubrogepant | 14 | suppressed |
| Fluconazole | Fluconazole | 13 | suppressed |
| Mupirocin | Mupirocin | 13 | 12 |
| Naproxen | Naproxen | 13 | suppressed |
| Nitroglycerin | Nitroglycerin | 13 | 11 |
| Oxybutynin Chloride | Oxybutynin Chloride | 13 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 13 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 12 | suppressed |
| Ammonium Lactate | Ammonium Lactate | 12 | suppressed |
| Brilinta | Ticagrelor | 12 | suppressed |
| Entacapone | Entacapone | 12 | suppressed |
| Erythromycin | Erythromycin Base | 12 | suppressed |
| Glucagon Emergency Kit | Glucagon | 12 | suppressed |
| Ramipril | Ramipril | 12 | suppressed |
| Risedronate Sodium | Risedronate Sodium | 12 | suppressed |
| Synthroid | Levothyroxine Sodium | 12 | suppressed |
| Anastrozole | Anastrozole | 11 | suppressed |
| Atrovent Hfa | Ipratropium Bromide | 11 | suppressed |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 11 | suppressed |
| Constulose | Lactulose | 11 | suppressed |
| Indomethacin | Indomethacin | 11 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 11 | suppressed |
| Ranolazine Er | Ranolazine | 11 | suppressed |
| Sotalol | Sotalol Hcl | 11 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $2,162.27 · 40 records | Teva Pharmaceuticals USA, Inc. | AREXVY, AUSTEDO XR, BREZTRI, EVENITY, FARXIGA, Intracept, JARDIANCE, Kerendia, Korlym, LEQVIO, Leqembi, MOUNJARO, OTEZLA, Ozempic, QULIPTA, REPATHA, REXULTI, REZDIFFRA, ROXYBOND, UBRELVY, VOQUEZNA, ZENPEP, ZEPBOUND, ZORYVE | 16 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error